Sugi Predict

Sugi Predict / Compounds / SCHEMBL24251983

SCHEMBL24251983

SCHEMBL24251983

C#Cc1ccc2sc(C3CCC3)nc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ DYRK1A Q13627 1/20 0.38
▸ UBE2M P61081 10/20 0.35
▸ DCUN1D1 Q96GG9 10/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ TP53 P04637 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ GAA P10253 3/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ TRPV1 Q8NER1 1/20 0.34
▸ LMNA P02545 3/20 0.33
▸ GFER P55789 1/20 0.33
▸ ALOX12 P18054 1/20 0.33
▸ POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24251981 0.94 NPC1 (0.49) NPC1RAB9AKMT2AMEN1DYRK1A
SCHEMBL24251984 0.74 NPC1 (0.36) NPC1RAB9AKMT2AMEN1UBE2M
SCHEMBL24445074 0.74 NPC1 (0.50) NPC1RAB9AKMT2AMEN1UBE2M
SCHEMBL20783885 0.74 NPC1 (0.50) NPC1RAB9AKMT2AMEN1UBE2M
SCHEMBL24092782 0.74 NPC1 (0.50) NPC1RAB9AKMT2AMEN1UBE2M
SCHEMBL13864072 0.73 NPC1 (0.49) NPC1RAB9AKMT2AMEN1UBE2M
SCHEMBL13082023 0.73 NPC1 (0.49) NPC1RAB9AKMT2AMEN1DYRK1A
SCHEMBL2914048 0.73 NPC1 (0.49) NPC1RAB9AKMT2AMEN1DYRK1A
SCHEMBL1744058 0.73 KMT2A (0.73) KMT2AMEN1UBE2MDCUN1D1ALDH1A1
SCHEMBL24251979 0.71 SMN1; SMN2 (0.52) NPC1RAB9AKMT2ADYRK1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 — — US disclosed
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-09-28 — — US disclosed
EP-4169922-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-04-26 — — EP disclosed
EP-4169922-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2023-04-26 — — EP disclosed
WO-2022033532-A1 FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海和誉生物医药科技有限公司 2022-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303575-A1 FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF FGFR3, FGFR1, FGFR4 NPC1 2173/4885RAB9A 3048/4885KMT2A 2210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.